# US 2008/0306064 A1 · Benzimidazole Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306064 A1
- Document ID: US20080306064A1
- Status: Published application
- Kind: A1
- Application number: 11/996,222
- Filed: 2006-07-19
- Published: 2008-12-11
- Earliest claimed: 2005-07-21
- Inventors: Lyndon Nigel Brown; Clive McCarthy; Neil John Press; Nicolas Soldermann
- Web page: https://patentgrep.com/patent/US20080306064A1

## CPC

- C07D 405/12: linked by a chain containing hetero atoms as chain links
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Benzimidazole derivatives, methods of preparing the same and their pharmaceutical uses for the treatment of inflammatory diseases including COPD.

## Claims

### Claim 1

A compound of formula I
in free or salt form, where
R1 is hydrogen or C1-C8-alkyl;
R2 is phenyl substituted at one position by fluoro and at another position by fluoro, chloro or C1-C8-alkyl, and R3 and R4 are both hydrogen;
or R2 is phenyl monosubstituted by chloro or phenyl, and R3 and R4 are both hydrogen;
or R2 is phenyl substituted at one, two or three positions by halo, and one of R3 and R4 is hydrogen, and the other of R3 and R4 is —SO2-NH2, C1-C8-alkylthio optionally substituted by C6-C10-aryl,C1-C8-alkylsulfinyl optionally substituted by C6-C10-aryl, C1-C8-alkylsulfohyl optionally substituted by C6-C10-aryl, or a 5-,or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur;
or R2 is phenyl substituted at one, two or three positions by halo, R3 is hydrogen, and R4 is fluoro;
or R2 is a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen and oxygen, R3 and R4 are independently hydrogen, halo, cyano, hydroxy, nitro, carboxy, aminocarbonyl, C1-C8-alkyl, C1-C8-alkenyl, C1-C8-alkynyl, C1-C8-haloalkyl, C1-C8-alkylthio optionally substituted by C6-C10-aryl, C1-C8-alkylsulfinyl optionally substituted by C6-C10-aryl, C1-C8-alkylsulfonyl optionally substituted by C6-C10-aryl, C1-C8-alkoxy, C1-C8-haloalkbxy, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C8-alkyl, C3-C8-cycloalkyl-oxy, —CO—NR5R6, —NH-SO2R7, —NH—COH, —SO2NH2, or a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur,
or R3 and R4 together form a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur, and R5, R6 and R7 are independently hydrogen or C1-C8-alkyl; or
or R2 is C1-C8-alkyl optionally-substituted by a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur, R3 and R4 are independently hydrogen, halo, cyano, hydroxy, nitro, carboxy, arninocarbonyl, C1-C8-alkyl, C1-C8-alkenyl, C1-C8-alkynyl, C1-C8-haloalkyl, C1-C8-alkylthio optionally substituted by C6-C10-aryl, C1-C8-alkylsulfinyl optionally substituted by C6-C10-aryl, C1-C8-alkylsulfonyl optionally substituted by C6-C10-aryl, C1-C8-alkoxy, C1-C8-haloalkoxy, C3-C8-cycloalkyl, C3-C8-cycloalkyl-C1-C8-alkyl, C3-C8-cycloalkyl-oxy, —CO-NR5R6, —NH-SO2R7, —NH—COH, —SO2NH2, or a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur, or R3 and R4 together form a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur,-and R5, R6 and R7 are independently hydrogen or C1-C8-alkyl.

### Claim 2 (depends on 1)

A compound according to claim 1, where
R1 is hydrogen;
R2 is phenyl substituted at one position by fluoro and at another position by fluoro, chloro or C1-C8-alkyl, and R3 and R4 are both hydrogen;
or R2 is phenyl monosubstituted by chloro or phenyl, and R3 and R4are both hydrogen; or R2 is phenyl substituted at one, two or three positions by halo, and one of R3 and R4 is hydrogen, and the other of R3 and R4-is —SO2-NH2, C1-C8-alkylthio optionally substituted by C6-C10-aryl, C1-C8-alkylsulfonyl optionally substituted by C6-C10-aryl, or a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur;
or R2 is phenyl substituted at one, two or three positions by halo, R3 is-hydrogen, and R4 is fluoro;
or R2 is a 5-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen and oxygen, and R3 and R4 are both hydrogen;
or R2 is C1-C8-alkyl optionally substituted by a 5- or 6membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur, and R3 and R4 are independently hydrogen or halo.

### Claim 3 (depends on 1)

A compound according to claim 1, where
R1 is hydrogen;
R2 is phenyl substituted at one position by fluoro and at another position by fluoro, chloro or C1-C4-alkyl, and R3 and R4 are both hydrogen;
or R2 is phenyl monosubstituted by chloro or phenyl, and R3 and R4 are both hydrogen;
or R2 is phenyl substituted at one, two or three positions by halo, and one of R3 and R4 is hydrogen, and the other of R3 and R4 is —SO2-NH2, C1-C4-alkylthio optionally substituted by phenyl, C1-C4-alkylsulfonyl optionally substituted by phenyl, or a 5- or 6-membered heterocyclic group containing at least one ring heteroatom selected from nitrogen, oxygen and sulphur; or R2 is phenyl substituted at one, two or three positions by halo, R3 is hydrogen, and R4 is fluoro;
or R2 is C1-C4-alkyl optionally substituted by a 5- or 6-membered heterocyclic group containing at least one oxygen as the heteroatom, and R3 and R4 are, independently hydrogen or halo.

### Claim 4 (depends on 1)

A compound according to claim 1 selected from the group consisting of

### Claim 5

(canceled)

### Claim 6 (depends on 1)

A compound according to claim 1 in combination with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising as active ingredient a compound according to claim 1, optionally together with a pharmaceutically acceptable diluent or carrier.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

A process for the preparation of a compound of formula I as claimed in claim 1 which comprises
(i) (A) for the preparation of compounds of formula I, cyclising a compound of formula IIa or IIb in either case optionally in protected form
where R1, R2, R3, and R4 are as defined in claim 1, and deprotecting where necessary;
(B) for the preparation of compounds of formula I where R1 is hydrogen, reacting a compound of formula IIa or IIIb in either case-optionally in protected form
where R3 and R4 are as defined in claim 1 and R8 is C1-C4-alkyl, with: a compound of formula IV
where R2 is as defined in claim 1 in the presence of a coupling agent, and deprotecting where necessary; or
(C) for the preparation of compounds of formula I where at least one of R3 and R4 is C1-C8-alkylsulfinyl or C1-C8-alkylsulfonyl in either case optionally substituted by C6-C10-aryl, oxidising a compound of formula I where R1 and R2 are as defined in claim 1, and at least one of R3 and R4 as defined in claim 1 is C1-C8-alkylthio optionally substituted by C8-C10-aryl, or a protected form thereof, and deprotecting where necessary; and
(ii) recovering the product in free-or salt form.

### Claim 11 (depends on 2)

A compound according to claim 2 in combination with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition.

### Claim 12 (depends on 3)

A compound according to claim 3 in combination with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition.

### Claim 13 (depends on 4)

A compound according to claim 4 in combination with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said compound and said drug substance being in the same or different pharmaceutical composition.

### Claim 14 (depends on 2)

A pharmaceutical composition comprising as active ingredient a compound-according to claim 2, optionally together with a pharmaceutically acceptable diluent or carrier.

### Claim 15 (depends on 3)

A pharmaceutical composition comprising as active ingredient a compound according to claim 3, optionally together with a pharmaceutically acceptable diluent or carrier.

### Claim 16 (depends on 4)

A pharmaceutical composition comprising as active ingredient a compound according to claim 4, optionally together with a pharmaceutically acceptable diluent or carrier.
